A body shape index (ABSI) reflects body composition changes in response to testosterone treatment in obese men.
Journal
International journal of obesity (2005)
ISSN: 1476-5497
Titre abrégé: Int J Obes (Lond)
Pays: England
ID NLM: 101256108
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
25
07
2018
accepted:
10
12
2018
revised:
04
12
2018
pubmed:
10
1
2019
medline:
2
6
2020
entrez:
10
1
2019
Statut:
ppublish
Résumé
Interventions such as testosterone treatment may change body composition and metabolic outcomes without substantial changes in weight and BMI. Using testosterone treatment as a paradigm, we hypothesized that a body shape index (ABSI) reflects body composition changes more accurately than traditional markers, such as weight, BMI and waist circumference. Secondary analysis of a 56-week RCT in 100 dieting obese men with low-normal testosterone receiving testosterone treatment or placebo, and subsequent off-treatment follow-up. At the end of the trial period, ABSI-unlike weight, BMI or waist circumference-had significantly decreased in the treatment group, compared with placebo (mean adjusted difference -0.18 [95% CI: -0.32, -0.05] × 10 A readily obtainable anthropomorphic measure, ABSI reflects the differential loss of fat mass mediated by testosterone in dieting obese men more closely than BMI or waist circumference. It may serve as a clinically useful marker to monitor body composition changes, particularly in response to interventions.
Sections du résumé
BACKGROUND
Interventions such as testosterone treatment may change body composition and metabolic outcomes without substantial changes in weight and BMI.
OBJECTIVES
Using testosterone treatment as a paradigm, we hypothesized that a body shape index (ABSI) reflects body composition changes more accurately than traditional markers, such as weight, BMI and waist circumference.
INTERVENTION
Secondary analysis of a 56-week RCT in 100 dieting obese men with low-normal testosterone receiving testosterone treatment or placebo, and subsequent off-treatment follow-up.
RESULTS
At the end of the trial period, ABSI-unlike weight, BMI or waist circumference-had significantly decreased in the treatment group, compared with placebo (mean adjusted difference -0.18 [95% CI: -0.32, -0.05] × 10
CONCLUSIONS
A readily obtainable anthropomorphic measure, ABSI reflects the differential loss of fat mass mediated by testosterone in dieting obese men more closely than BMI or waist circumference. It may serve as a clinically useful marker to monitor body composition changes, particularly in response to interventions.
Identifiants
pubmed: 30622310
doi: 10.1038/s41366-018-0311-y
pii: 10.1038/s41366-018-0311-y
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM